Contribute Try STAT+ Today

The new CEO of Legend Biotech says the company has seen no indication that it is the target of a Chinese investigation that has resulted in the arrest of his predecessor as well as employees of its parent company.

In an interview with STAT, CEO Ying Huang acknowledged the authorities’ investigation — said to focus on potential violations of import and export regulations — is ongoing. But he said Legend has no reason to believe it is currently a target. Ying also noted that, although former CEO Frank Zhang has been arrested, neither he nor other employees of Legend’s parent company, Genscript, have been charged.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.